glp 1 fda Lilly is now pharma's top revenue company. It just got approval for an oral GLP-1, but Wall Street isn't celebrating US FDA accepts Novo Nordisk's

NOW products are being tested to determine such things as effectiveness for joint support, quality of life for cancer patients, cardiovascular support, and athletic endurance

Moio, L., Etievant, P

2 Methodology A structured literature search was conducted using PubMed/MEDLINE and Google Scholar, with the Boolean search string: (GLP-1 receptor agonist OR GLP-1RA) AND (multifaceted roles OR pleiotropic effects)

For wound healing and scar reduction Acute wound healing: Dose: 2-3mg daily Frequency: Daily until healed Route: Near wound (subcutaneous, NOT into wound) Duration: 2-6 weeks depending on wound Chronic wound protocol: Dose: 2-3mg daily Frequency: Daily Duration: 4-12 weeks Can inject near wound or systemic Scar reduction: Dose: 1-2mg 3-5x weekly Inject near scar tissue 8-16 weeks Old scars need longer (24+ weeks) Expected wound healing: 50-70% faster healing time Reduced scar formation Better tissue quality Less inflammation For general tissue regeneration Systemic tissue health: Dose: 1-2mg Frequency: 3-5x weekly Route: Subcutaneous (any site) Duration: Ongoing for health optimization Benefits: Overall tissue repair Reduced inflammation Better recovery from injuries Enhanced collagen throughout body Improved joint and connective tissue Who uses this: Athletes for recovery Aging individuals for tissue maintenance After surgery for healing Chronic inflammation issues See our best peptides for injury recovery , fast injury healing , best peptides for joint pain , and best peptides for tendon repair